Pacira BioSciences (PCRX) Operating Expenses (2010 - 2026)

Pacira BioSciences has reported Operating Expenses for 17 years, with the latest figure at $188.1 million in Q2 2026.

• On a quarterly basis, Operating Expenses rose 9.0% year-over-year to $188.1 million in Q2 2026; TTM through Jun 2026 was $726.3 million, a 10.35% decrease from a year earlier, with the FY2025 full-year figure at $707.2 million, down 8.67% from the prior year.
• Operating Expenses was $188.1 million for Q2 2026 at Pacira BioSciences, up from $170.5 million in the prior quarter.
• The five-year high for Operating Expenses was $308.1 million in Q3 2024, with the low at $129.6 million in Q2 2023.
• Average Operating Expenses over 5 years is $168.6 million, with a median of $163.0 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses soared 110.73% in 2024, then slumped 43.8% in 2025.
• Over 5 years, Operating Expenses stood at $181.8 million in 2022, then declined by 18.57% to $148.1 million in 2023, then increased by 9.77% to $162.5 million in 2024, then climbed by 19.68% to $194.5 million in 2025, then slipped by 3.29% to $188.1 million in 2026.
• The last three Operating Expenses figures came in at $188.1 million (Q2 2026), $170.5 million (Q1 2026), and $194.5 million (Q4 2025), per Business Quant data.